Stevens-Johnson Syndrome Associated with Malarone Antimalarial Prophylaxis

Emberger, Michael; Lechner, Arno Nichael; Zelger, Bernhard
July 2003
Clinical Infectious Diseases;7/1/2003, Vol. 37 Issue 1, pe5
Academic Journal
To the best of our knowledge, Stevens-Johnson syndrome (SJS) has not been reported previously as an adverse reaction to Malarone, which is a combination of atovaquone and proguanil hydrochloride used for antimalarial prophylaxis and therapy. We describe a 65-year-old patient who had SJS with typical clinical and histopathological findings associated with the use of Malarone prophylaxis for malaria. This report should alert physicians to this severe cutaneous reaction, and Malarone should be added to the list of drugs that can potentially cause SJS.


Related Articles

  • Chloroquine most common antimalarial for children in Nigeria.  // PharmacoEconomics & Outcomes News;2/7/2009, Issue 571, p7 

    The article discusses research being done on chloroquine, the most common antimalarial for children in Nigeria. It references a study by C. V. Ukwe and O. K. Ekwunife published in the December 2008 issue of the "Pharmacoepidemiology and Drug Safety. It is noted that chloroquine is the most...

  • Strategic solution to malaria eradication in Pakistan. Malik, Madeeha; Hassali, Mohamed A. A.; Shafie, Asrul A.; Hussain, Azhar // Journal of Pharmacy Practice & Research;Mar2011, Vol. 41 Issue 1, p73 

    A letter to the editor is presented which is concerned with malaria eradication in Pakistan.

  • Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilance.  // Malaria Journal;2011, Vol. 10 Issue 1, p230 

    The article reports on a study indicating the continuing use of ineffective anti-malaria drugs in Sagamu, Nigeria. It states anti-malaria medicines including monotherapies remain widely available for purchase in the area. It states the cost of monotherapies might be the major factor for the...

  • The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites. Delves, Michael; Plouffe, David; Scheurer, Christian; Meister, Stephan; Wittlin, Sergio; Winzeler, Elizabeth A.; Sinden, Robert E.; Leroy, Didier // PLoS Medicine;Feb2012, Vol. 9 Issue 2, p1 

    Background: Malaria remains a disease of devastating global impact, killing more than 800,000 people every year-the vast majority being children under the age of 5. While effective therapies are available, if malaria is to be eradicated a broader range of small molecule therapeutics that are...

  • Increasing Access to Subsidized Artemisininbased Combination Therapy through Accredited Drug Dispensing Outlets in Tanzania. Rutta, Edmund; Kibassa, Bryceson; McKinnon, Brittany; Liana, Jafary; Mbwasi, Romuald; Mlaki, Wilson; Embrey, Martha; Gabra, Michael; Shekalaghe, Elizabeth; Kimatta, Suleiman; Sillo, Hiiti // Health Research Policy & Systems;2011, Vol. 9 Issue 1, p22 

    Background: In Tanzania, many people seek malaria treatment from retail drug sellers. The National Malaria Control Program identified the accredited drug dispensing outlet (ADDO) program as a private sector mechanism to supplement the distribution of subsidized artemisinin-based combination...

  • Vaccine halves malaria episodes in children in Africa. Tanne, Janice Hopkins // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/29/2011, Vol. 343 Issue 7829, p868 

    The article offers information on a medical research in which it has been found that the new antimalaria vaccine developed by pharmaceutical company GlaxoSmithKline has halved the number of first clinical episodes of malaria and severe malaria in children in Africa. As reported, the lead author...

  • A clinical trial of 'AM', a Ugandan herbal remedy for malaria. Willcox, Merlin L. // Journal of Public Health Medicine;Sep1999, Vol. 21 Issue 3, p318 

    Background Mortality and morbidity from malaria is still high in Africa, and may further increase as resistance to antimalarial drugs spreads. Many people rely on herbal medicines as the first line of treatment. Yet there has been very little clinical research into their effectiveness.

  • Plants traditionally prescribed to treat tazo (malaria) in the eastern region of Madagascar. Randrianarivelojosia, Milijaona; Rasidimanana, Valérie T.; Rabarison, Harison; Cheplogoi, Peter K.; Ratsimbason, Michel; Mulholland, Dulcie A.; Mauclère, Philippe // Malaria Journal;2003, Vol. 2, p1 

    Background: Malaria is known as tazo or tazomoka in local terminology in Madagascar. Within the context of traditional practice, malaria (and/or malaria symptoms) is commonly treated by decoctions or infusions from bitter plants. One possible approach to the identification of new antimalarial...

  • Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs). Kindermans, Jean-Marie; Vandenbergh, Daniel; Vreeke, Ed; Olliaro, Piero; D'Altilia, Jean-Pierre // Malaria Journal;2007, Vol. 6, p91 

    Background: Having reliable forecasts is critical now for producers, malaria-endemic countries and agencies in order to adapt production and procurement of the artemisinin-based combination treatments (ACTs), the new first-line treatments of malaria. There is no ideal method to quantify drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics